Roche
Roche bets on artificial intelligence to drive its next wave of medicines
Roche is placing artificial intelligence at the centre of its pharmaceutical strategy as it seeks to accelerate drug discovery and rebuild growth after patent expiries and research setbacks. The article should assess how AI is being used in research and development, examine the company’s pipeline of potential medicines through 2030, and consider the opportunities and risks for Switzerland’s life-sciences sector.
AISeptember 28, 2026

Article content structure is incomplete. Please refresh or contact support.